|
|
|
|
Atrium acquires Nutri-Health Supplements
Atrium has acquired Nutri-Health Supplements (NHS) for a first consideration of $23.9 million fully paid in cash at the closing of the transaction.Two additional earn-out payments have been structured based on NHS's 2009 and 2010 EBITDA...
|
|
|
Dor wins FDA clearance to initiate Phase III graft-versus-host disease study
An agreement via the special protocol assessment (SPA) procedure is an agreement with the FDA that a Phase III clinical trial's design (endpoints, sample size, control group and statistical analyses) is acceptable to support a regulatory...
|
|
|
CureVac wins approval to initiate Phase I/IIa prostate cancer vaccine study
The Phase I/IIa trial is designed to assess the safety, tolerability and biological activity of the vaccine.CureVac expects to start the treatment of the first patient in March 2009. First results from the Phase I/IIa trial are expected...
|
|
|
Ensign acquires Southland Healthcare Center
Ensign has purchased the facility from an out-of-state operator who acquired the property in November 2006.Barry Port, president of the Ensign subsidiary that will include Southland, noted that the physical plant is in good condition and...
|
|
|
Galapagos to advance cachexia drug into preclinical development
This candidate drug is a small molecule that Galapagos has developed in its selective androgen receptor modulator program and which has demonstrated successful proof of concept in animal studies.According to Galapagos, its preclinical...
|
|
|
RA Group Holdings completes acquisition of National Renal Alliance
Michael Klein, CEO of Renal Advantage, said: 'We are pleased to announce the completion of our acquisition of National Renal Alliance.We remain confident in our belief that the combination of our two companies' cultures, philosophies and...
|
|
|
Bionovo reports encouraging data from estrogen receptor modulators study
The data showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.The study was conducted by...
|
|
|
Valeant completes acquisition of Dow Pharmaceutical Sciences
Valeant Pharmaceuticals develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology.Valeant completes acquisition of Dow Pharmaceutical Sciences.
|
|
|
Response Genetics amends master service agreement with GSK
This agreement extends the current agreement between the companies for a two-year period and names Response Genetics as preferred provider of genetic testing services to GlaxoSmithKline (GSK) and its affiliated companies.In anticipation...
|
|
|
Adaltis names new vice-president of finance
Prior to joining Adaltis, Ms Cheung worked at Sanofi and at Dystar China, a spin off company of BASF.Ms Cheung will replace Jacques Deforges, the company's current vice-president and CFO, who will leave the company to pursue other...
|
